TEAM MEETING: From left, Brenton DeBoef, professor of chemistry at the University of Rhode Island, and Alcinous Pharmaceutical team members Nicholas DaSilva, CEO and Ph.D. student in the URI College of Pharmacy; Benjamin Barlock, chief technology officer and Ph.D. student in the URI College of Pharmacy; David Worthen, chief operations officer and URI assistant professor in the Department of Biomedical and Pharmaceutical Sciences and the Department of Chemical Engineering; and Ken Rose, chief scientific officer and Ph.D. student in the URI College of Pharmacy, discuss Alcinous’ latest research project. / PBN PHOTO/RUPERT WHITELEY
Five weeks prior to celebrating its first year in business, Alcinous Pharmaceuticals received a $50,000 Innovation Voucher from R.I. Commerce Corp. The microcompany had been pursuing the state funding for quite a while, said Ken Rose, chief scientific officer, adding the announcement was a “relief.” One of three companies approved to receive voucher funding in…
You must be a paid subscriber to read this content.
To keep reading and receive unlimited access subscribe today for only $1.
Subscribe NowAlready a Subscriber?
Login now
Want to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.
Want to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.
